AbbVie Inc.

AbbVie reported mixed first-quarter 2026 results with net revenues increasing 12.4% to $15.002 billion, while net earnings attributable to AbbVie Inc. decreased 46.0% to $695 million, and diluted EPS fell 45.8% to $0.39. The decline in profitability was primarily driven by a significant increase in acquired IPR&D and milestones, including a $650 million upfront payment for a license agreement with RemeGen. Despite this, cash flows from operating activities saw a substantial increase to $3.829 billion.

AbbVie Inc., in collaboration with adMare BioInnovations, has awarded the AbbVie Biotechnology Innovators Award to RIME Therapeutics, a Montreal-based startup. This award aims to foster innovation and growth in Quebec's life sciences sector. RIME Therapeutics, founded in 2025, is developing a peptide-based drug discovery platform targeting protein-protein interactions for inflammation and immune disorders. The prize includes one year of free lab and office space, shared services at adMare Innovation Centre, and mentorship from AbbVie's commercial and scientific leaders, supporting RIME's research in areas aligned with AbbVie's therapeutic focus.

AbbVie, in partnership with adMare BioInnovations, recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This award aims to foster innovation and support growth in Quebec’s life sciences sector. RIME Therapeutics, founded in 2025, is a Montreal-based startup developing a peptide-based drug discovery platform for inflammation and immunology. The award provides RIME with one year of laboratory and office space at the adMare Innovation Centre, access to shared equipment, and mentorship from AbbVie's scientific and business leaders.

AbbVie Inc. reported strong first-quarter 2026 financial results, with net revenues reaching $15.002 billion, a 12.4% increase, and adjusted diluted EPS growing 7.7% to $2.65. The company exceeded expectations and raised its full-year 2026 adjusted diluted EPS guidance to $14.08 - $14.28. Key growth drivers like Skyrizi, Rinvoq, and the Neuroscience portfolio delivered robust performance, while the company also announced a new FDA approval for Venclexta and submitted applications for Skyrizi and Rinvoq for new indications, though it received a CRL for trenibotulinumtoxinE due to manufacturing process inquiries.

AbbVie has released its financial results for the third quarter of 2025. The details of the results are contained within the press release furnished as an exhibit to the 8-K filing, and will be of interest to investors tracking the company's performance.

AbbVie announced preliminary results for Q4 2025 and updated its full-year 2025 adjusted diluted earnings per share guidance to $9.90-$9.94, reflecting a $1.3 billion pre-tax acquired IPR&D and milestones expense. This expense will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.71.

AbbVie filed an 8-K announcing its financial results for the fourth quarter and full year ended December 31, 2025. The press release, furnished as an exhibit, contains detailed information about the company's performance, which is important for investors to assess AbbVie's financial health and future prospects.

AbbVie has entered into an underwriting agreement to issue and sell $8.0 billion in aggregate principal amount of senior notes due between 2028 and 2066. The offering includes floating rate notes and fixed-rate notes with varying interest rates, with the proceeds likely used for general corporate purposes, including debt refinancing or acquisitions.

AbbVie has completed a previously announced underwritten public offering of senior notes, raising a total of $8.0 billion. The offering includes various series of notes with different interest rates and maturity dates, ranging from 2028 to 2066, providing AbbVie with significant capital.

AbbVie's upcoming annual meeting includes a proposal to eliminate the supermajority voting requirement, potentially making it easier for shareholders to enact changes. This change could impact corporate governance and shareholder rights.